HALCION (triazolam) by Pfizer is benzodiazepine. First approved in 1982.
Drug data last refreshed 13h ago
HALCION (triazolam) is a short-acting benzodiazepine approved in 1982 for the short-term treatment of insomnia. It works by binding to GABA-A receptors in the brain and enhancing GABAergic synaptic inhibition to promote sleep. The drug is a small-molecule oral tablet indicated for insomnia, though safety data show significant abuse and overdose signals.
Declining utilization and LOE-approaching status signal a mature, contracted franchise with limited growth opportunities and lean team structures.
benzodiazepine. Triazolam exerts its effect for the short-term treatment of insomnia through binding to the benzodiazepine site of the gamma-aminobutyric acid-A (GABA A ) receptors in the brain and enhances GABA-mediated synaptic inhibition.
Benzodiazepine
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers
A Study to Determine Whether an Oral Drops Formulation of Triazolam is Bioequivalent to a Tablet Formulation in Healthy Subjects
Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption
A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure
Worked on HALCION at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on HALCION offers limited career upside; the product is in decline with minimal hiring and no clinical pipeline. Roles are primarily defensive and focused on compliance, pharmacovigilance, and managing the product's legacy market share rather than growth or innovation.